Statutory Restrictions on Consolidated Stockholders' Equity and Investments

12 Months Ended

Dec. 31, 2023

Statutory Restrictions on Consolidated Stockholders' Equity and Investments [Abstract]

Statutory Restrictions on Consolidated Stockholders' Equity and Investments

Statutory Accounting and Restrictions on Consolidated Shareholders’ Equity and Investments

The Consolidated Financial Statements have been prepared in conformity with GAAP, which differ in some respects from statutory accounting practices prescribed or permitted in the preparation of financial statements for submission to insurance regulatory authorities.

Combined capital and surplus on a statutory basis was $243.3 million and $235.6 million as of December 31, 2023 and 2022, respectively. Net income on a statutory basis was $31.6 million and $35.6 million and for the years ended December 31, 2023 and 2022, respectively.

The Company has designated approximately $52.1 million and $53.3 million of retained earnings as of December 31, 2023 and 2022, respectively, as appropriated to reflect the required statutory premium and supplemental reserves. Refer to Note 8 for the tax treatment of the statutory premium reserve.

As of December 31, 2023 and 2022, approximately $113.0 million and $110.3 million, respectively, of consolidated shareholders’ equity represents net assets of the Company’s subsidiaries that cannot be transferred in the form of dividends, loans or advances to the parent company under statutory regulations without prior insurance department approval. During 2024, the maximum distributions the insurance subsidiaries can make to the Company without prior approval from applicable regulators total approximately $17.5 million.

Fixed maturity securities with fair market values totaling approximately $6.7 million at December 31, 2023 and 2022, are deposited with the insurance departments of the states in which business is conducted.